類器官CHIR-99021
| 參考價 | ￥2112.00 |
- 公司名稱 普邁精醫(yī)科技（北京）有限公司
- 品牌其他品牌
- 型號
- 所在地北京市
- 廠商性質代理商
- 更新時間2024/11/6 18:07:55
- 訪問次數 523
| 10mg | 2112.00元 | 10 mg可售 |
聯系方式：林明400-609-0003 查看聯系方式
聯系我們時請說明是化工儀器網上看到的信息，謝謝!
| 供貨周期 | 現貨 |
|---|
類器官CHIR-99021
類器官（Organoids）是指將成體干細胞或多能干細胞在體外三維培養(yǎng)形成的具有一定空間結構的組織類似物。類器官在組織結構、細胞類型、自我更新能力和功能等方面與來源組織高度一致，從而在發(fā)育生物學、疾病造模、精準醫(yī)學、藥物研發(fā)、基因和細胞療法、感染和免疫以及再生醫(yī)學等生物醫(yī)學的多個領域展現出*的優(yōu)勢。
產品介紹DESCRIPTION
| Background | CHIR-99021 is a potent and selective GSK-3α/β inhibitor with IC50s of 10 nM and 6.7 nM. Laduviglusib shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. Laduviglusib is also a potent Wnt/β-catenin signaling pathway activator. Laduviglusib enhances mouse and human embryonic stem cells self-renewal. Laduviglusib induces autophagy[1][2][3]. | ||
| Alias | Laduviglusib; CT99021 | ||
| M. W t | 465.34 | ||
| Formula | C22H18Cl2N8 | ||
| CAS No | 252917-06-9 | ||
| Storage | Powder | -20°C | 3 years |
| 4°C | 2 years C22H18Cl2N8 | ||
| In solvent | -80°C | 6 months | |
| -20°C | 1 month | ||
| Solubility | DMSO | 16.67 mg/mL(35.82 mM) | |
| H2O | < 0.1 mg/mL(insoluble) | ||
BIOLOGICAL ALTIVITY
In Vitro
CHIR-99021 inhibits human GSK-3β with Ki values of 9.8 nM[1]. Laduviglusib is a small organic molecule that inhibits GSK3α and GSK3β by competing for their ATP-binding sites.In vitro kinase assays reveal that Laduviglusib specifically inhibits GSK3β (IC50=~5 nM) and GSK3α (IC50=~10 nM), with little effect on other kinases[4]. In the presence of Laduviglusib the viability of the ES-D3 cells is reduced by 24.7% at 2.5 μM, 56.3% at 5 μM, 61.9% at 7.5 μM and 69.2% at 10 μM Laduviglusib with an IC50 of 4.9 mm[2].
In Vivo
In ZDF rats, a single oral dose of Laduviglusib (16 mg/kg or 48 mg/kg) rapidly lowers plasma glucose, with a maximal reduction of nearly 150 mg/dl 3-4 h after administration[1]. Laduviglusib (2 mg/kg) given once, 4 h before irradiation, significantly improves survival after 14.5 Gy abdominal irradiation (ABI). Laduviglusib treatment significantly blocks crypt apoptosis and accumulation of p-H2AX+ cells, and improves crypt regeneration and villus height. Laduviglusib treatment increases Lgr5+ cell survival by blocking apoptosis, and effectively prevents the reduction of Olfm4, Lgr5 and CD44 as early as 4 h[5].
類器官CHIR-99021
采購中心
化工儀器網